Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
In a small, controlled study of 18 people with treatment-resistant major depression, a single intravenous dose of the NMDA receptor antagonist ketamine (0.5 mg/kg) produced rapid drops in depression scores. Improvement began within about 2 hours and remained statistically significant compared with placebo for up to 1 week. The study…
The endocannabinoid system (ECS) is a widespread brain signaling system made of cannabinoid receptors, naturally made lipid messengers, and the enzymes that make and break those messengers. The two best-studied messengers are 2-AG and anandamide, and they are produced and degraded by different enzyme pathways. CB1 receptors are common in…
This review describes the endocannabinoid system (ECS) as a widespread network of natural cannabinoids, cannabinoid receptors (mainly CB1 and CB2), and the enzymes that make and break those chemicals. The ECS helps shape brain development and adjusts how neurons communicate. The authors note that THC is the main psychoactive part…
This paper reviews genetic studies that link several genes to higher risk for ADHD. It says problems in the brain's reward system—especially low dopamine activity—may make people seek things that raise dopamine. The authors propose that these gene variants form a “reward deficiency syndrome” (RDS) that may include ADHD, and…
This webpage explains how DoktorABC offers medical cannabis services in Germany. You fill an online medical questionnaire, a licensed doctor reviews it, and may issue a prescription. The page also describes costs, delivery times, legal status, types of products, common effects of THC and CBD, and possible side effects.
This review says that the main active part of cannabis, THC, acts at the brain's CB1 receptor to produce rewarding effects, reinforce smoking, and can lead to dependence and withdrawal. Evidence comes from animal and human studies. Higher THC strength raises blood THC levels and may raise the chance of…
Most of the included studies were at high risk of bias and the overall quality of the evidence ranged from low to very low on most outcomes. Although amphetamines seem efficacious at reducing the core symptoms of ADHD in the short term, they were associated with a number of adverse…
This review compares THC and CBD, two main chemicals made by the Cannabis plant. It explains how they work differently in the body and brain, how people take them (smoking, vaping, eating), and key numbers about blood levels after different doses. The paper notes rising THC strengths in some products,…
Ibogaine is a psychoactive chemical from a West African shrub that some clinics use to help people stop using opioids or stimulants. Small studies, animal research, and many personal reports say a single high dose can cut opioid withdrawal and reduce cravings. For example, one study found 50% of participants…
This study tested the cannabinoid THCV in two kinds of obese mice and in insulin-resistant liver and muscle cells. THCV did not change food intake or body weight, but it briefly raised energy use and improved how the animals handled glucose. In obese mice, THCV improved glucose tolerance and insulin…
In this small, double-blind, placebo-controlled crossover study, 10 healthy male, infrequent cannabis users took 10 mg oral THCV daily for five days and then received 1 mg IV THC on day five. THCV was safe and felt like placebo. Compared with placebo, THCV reduced some effects of THC (for example…
